Background/Aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of digestive cancer. Recurrence within one year after surgery is inevitable in most PDAC patients. Recently, cluster of differentiation 44 (CD44) has been shown to be associated with tumor initiation, metastasis and prognosis. This study aimed to explore the correlation of CD44 expression with clinicopathological factors and the role of CD44 in predicting early recurrence (ER) in PDAC patients after radical surgery. Materials and Methods: PDAC patients who underwent radical resection between January 1999 and March 2015 were enrolled in this study. Tumor recurrence within 6 months after surgery was defined as ER. Immunohistochemical staining was performed with anti-CD44 antibodies. The association between clinico - pathological parameters and CD44 expression was analyzed. Predictors for ER were also assessed with univariate and multivariate analyses. Results: Overall, 155 patients were included in this study. Univariate analysis revealed CA19-9 levels (p=0.014), CD44 histoscores (H-scores; p=0.002), differentiation (p=0.010), nodal status (p=0.005), stage (p=0.003), vascular invasion (p=0.007), lymphatic invasion (p<0.001) and perineural invasion (p=0.042) as risk factors for ER. In multivariate analysis, high CA19-9 levels and CD44 H-scores and poor differentiation independently predicted ER. Conclusion: High CA19-9 levels, CD44 Hscores and poor differentiation are independent predictors for ER in PDAC patients undergoing radical resection. Therefore, the determination of CD44 expression might help in identifying patients at a high risk of ER for more aggressive treatment after radical surgery.
CITATION STYLE
Hsu, C. P., Lee, L. Y., Hsu, J. T., Hsu, Y. P., Wu, Y. T., Wang, S. Y., … Hwang, T. L. (2018). CD44 predicts early recurrence in pancreatic cancer patients undergoing radical surgery. In Vivo, 32(6), 1533–1540. https://doi.org/10.21873/invivo.11411
Mendeley helps you to discover research relevant for your work.